Pharmaceutical Recognition & Awards

Recognizing & Rewarding the Pharmaceutical Industry's Constant Innovation

Pharmaceutical Industry Recognition AwardThe pharmaceutical industry demands constant innovation—innovation that calls for something beyond the same tired, off-the-shelf, cookie-cutter “employee recognition awards.”

In the galleries beginning on this page, you’ll see distinctive custom awards and commemoratives recognizing the industry’s ongoing efforts to deliver safe and effective medications to patients globally.

These milestones include:

  • FDA drug approvals
  • Clinical & preclinical trials
  • Treatment studies
  • Research collaborations
  • New drug launches
  • Licensing & commercialization agreements
  • Joint ventures
  • Financings & capital raises

The specific custom awards included here celebrate and reflect a broad range of activity and achievement.

Among the creative designs you’ll see here are:

  • A custom Lucite, incorporating an actual drug vial, celebrating FDA approval of an ovarian cancer treatment.
  • A custom crystal commemorating the submission of a new drug application (NDA) for a migraine therapy.
  • A crystal award recognizing the contribution of team members in a clinical trial of an antitumor therapy.
  • A custom Lucite award marking the first patient dosed in a clinical trial of a sleep apnea therapy.
  • A Lucite embedment commemorating a study for the treatment of solid tumor cancer.

Pharmaceutical Recognition & The Corporate Presence

At The Corporate Presence, we’ve been helping the pharmaceutical industry celebrate innovation and achievement for over 40 years. Whatever the milestone you’re seeking to commemorate, you can count on our expertise and experience to guide you through the process. Get that creative process started. Reach out to us today.

Pharmaceutical Product Launch Commemorative

Lucite commemorative, incorporating a drug vial, celebrating the first product shipment by generic pharmaceutical company Civica.

(9AKL475)
1 Image

Drug Vial Embedment Celebrating FDA Approval

Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)

1 Image

FDA Approval Commemorative with Embedded Drug Vial

Custom Lucite, with an embedded drug vial, celebrating FDA approval of Cosela. (20ADH005)

1 Image

Merck Clinical Study Commemorative

Crystal commemorative recognizing team members in a first in-human clinical study of an anti-tumor therapy.

(9AJH024)
1 Image

New Drug Application Custom Crystal

Custom crystal celebrating the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA). The application, related to Impel NeuroPharma’s migraine treatment INP104, was supported by a Phase 3, open-label STOP-301 Trial.

(20ALJ356)
2 Images
Crystal commemorative marking the submission to the Food and Drug Administration (FDA) of a New Drug Application (NDA). INP104 was developed for the acute treatment of migraine headaches.

Tumor Treatment Licensing Agreement Commemorative

Crystal commemorative marking a licensing and commercialization agreement between Corbus Pharmaceuticals and CSPC Pharmaceutical Group. The agreement centers on a potential treatment for tumors associated with lung, breast, and prostate cancers. (23AZH089)

1 Image

Crystal Commemorative for Pharmaceutical Launch

Custom crystal commemorative celebrating the launch of Wynzora Cream, a topical treatment for plaque psoriasis that received approval from the FDA (Food and Drug Administration) in 2020. The product launch resulted from a collaboration agreement between Denmark-based MC2 Therapeutics, and EPI Health, a specialty pharmaceutical firm headquartered in Charleston, South Carolina.

(21ADH022)
1 Image

Custom Commemorative for Drug Licensing Agreement

Custom crystal commemorative, incorporating a periodic table theme, marking a licensing and commercialization agreement for a cancer drug developed by Rockville, Maryland-based biotech firm GlycoMimetics. The agreement applies to mainland China, Hong Kong, Taiwan, and Macau.

(20ALJ071)
1 Image

Ogsiveo FDA Approval Commemorative

Crystal commemorative celebrating FDA approval of Ogsiveo, a treatment for desmoid tumors. (24aZH051)

1 Image

Contact Us For a Quote Today

"*" indicates required fields

Fill out our quote request form and an associate will be in contact with you as soon as possible.

 

Drop files here or
Accepted file types: tiff, gif, jpg, png, pdf, jpeg, Max. file size: 30 MB, Max. files: 6.
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.